[Hengrui Pharmaceuticals: Ruikang totumumab for injection has been included in the list of breakthrough therapies] On September 11, Hengrui Medicine (600276.SH) announced that the company's subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd.'s Ruikang totumumab for injection has been included in the list of breakthrough therapies by the Drug Evaluation Center of the State Food and Drug Administration. The proposed indication is to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR mutations in combination with bevacizumab. This drug is an antibody-drug conjugate targeting HER3. There is no similar drug approved to treat NSCLC in the world, and the cumulative R&D investment in related projects is approximately 355 million yuan.